BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu H, Norman GL, Shums Z, Worman HJ, Krawitt EL, Bizzaro N, Vergani D, Bogdanos DP, Dalekos GN, Milkiewicz P. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun. 2010;35:436-442. [PMID: 20932720 DOI: 10.1016/j.jaut.2010.09.005] [Cited by in Crossref: 93] [Cited by in F6Publishing: 85] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Shovman O, Agmon-levin N, Gilburd B, Martins T, Petzold A, Matthias T, Shoenfeld Y. A fully automated IIF system for the detection of antinuclear antibodies and antineutrophil cytoplasmic antibodies. Immunol Res 2015;61:135-40. [DOI: 10.1007/s12026-014-8588-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
2 Villalta D, Seaman A, Tiongson M, Warren C, Bentow C, Bizzaro N, Alessio MG, Porcelli B, Norman GL, Mahler M. Evaluation of a novel extended automated particle-based multi-analyte assay for the detection of autoantibodies in the diagnosis of primary biliary cholangitis. Clin Chem Lab Med 2020;58:1499-507. [PMID: 32286240 DOI: 10.1515/cclm-2020-0122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
3 Gatselis NK, Zachou K, Norman GL, Gabeta S, Papamichalis P, Koukoulis GK, Dalekos GN. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity. 2013;46:471-479. [PMID: 23777462 DOI: 10.3109/08916934.2013.801461] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
4 Hu SL, Zhao FR, Hu Q, Chen WX. Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis. PLoS One 2014;9:e101916. [PMID: 25010534 DOI: 10.1371/journal.pone.0101916] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
5 Mytilinaiou MG, Meyer W, Scheper T, Rigopoulou EI, Probst C, Koutsoumpas AL, Abeles D, Burroughs AK, Komorowski L, Vergani D, Bogdanos DP. Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis. Clinica Chimica Acta 2012;413:1211-6. [DOI: 10.1016/j.cca.2012.03.020] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
6 Kempinska-Podhorodecka A, Shums Z, Wasilewicz M, Wunsch E, Milkiewicz M, Bogdanos DP, Norman GL, Milkiewicz P. TRAF1 gene polymorphism correlates with the titre of Gp210 antibody in patients with primary biliary cirrhosis. Clin Dev Immunol 2012;2012:487521. [PMID: 23125866 DOI: 10.1155/2012/487521] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
7 Selmi C, Generali E, Gershwin ME. Rheumatic Manifestations in Autoimmune Liver Disease. Rheumatic Disease Clinics of North America 2018;44:65-87. [DOI: 10.1016/j.rdc.2017.09.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
8 Shuai Z, Wang J, Badamagunta M, Choi J, Yang G, Zhang W, Kenny TP, Guggenheim K, Kurth MJ, Ansari AA, Voss J, Coppel RL, Invernizzi P, Leung PSC, Gershwin ME. The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. Hepatology 2017;65:1670-82. [PMID: 28100006 DOI: 10.1002/hep.29059] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
9 Smyk D, Rigopoulou EI, Bizzaro N, Bogdanos DP. Hair dyes as a risk for autoimmunity: from systemic lupus erythematosus to primary biliary cirrhosis. Auto Immun Highlights. 2013;4:1-9. [PMID: 26000137 DOI: 10.1007/s13317-011-0027-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Rigopoulou EI, Roggenbuck D, Smyk DS, Liaskos C, Mytilinaiou MG, Feist E, Conrad K, Bogdanos DP. Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: lost and found. Autoimmun Rev. 2012;12:260-269. [PMID: 22571878 DOI: 10.1016/j.autrev.2012.04.005] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 6.2] [Reference Citation Analysis]
11 Smyk D, Rigopoulou EI, Baum H, Burroughs AK, Vergani D, Bogdanos DP. Autoimmunity and environment: am I at risk? Clin Rev Allergy Immunol. 2012;42:199-212. [PMID: 21337133 DOI: 10.1007/s12016-011-8259-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
12 Vierling JM. Autoimmune Hepatitis and Overlap Syndromes: Diagnosis and Management. Clin Gastroenterol Hepatol. 2015;13:2088-2108. [PMID: 26284592 DOI: 10.1016/j.cgh.2015.08.012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
13 Shimoda S, Tsuneyama K, Kikuchi K, Harada K, Nakanuma Y, Nakamura M, Ishibashi H, Hisamoto S, Niiro H, Leung PS. The role of natural killer (NK) and NK T cells in the loss of tolerance in murine primary biliary cirrhosis. Clin Exp Immunol. 2012;168:279-284. [PMID: 22519590 DOI: 10.1111/j.1365-2249.2012.04581.x.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Smyk D, Grammatikopoulos T, Daponte A, Rigopoulou EI, Bogdanos DP. Fetomaternal alloimmunity as a cause of liver disease. Auto Immun Highlights 2011;2:21-8. [PMID: 26000116 DOI: 10.1007/s13317-011-0019-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, Vincent C, Rust C, Parés A, Mason A, Marschall HU, Shapiro D, Adorini L, Sciacca C, Beecher-Jones T, Böhm O, Pencek R, Jones D; Obeticholic Acid PBC Monotherapy Study Group. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology 2018;67:1890-902. [PMID: 29023915 DOI: 10.1002/hep.29569] [Cited by in Crossref: 110] [Cited by in F6Publishing: 100] [Article Influence: 27.5] [Reference Citation Analysis]
16 Norman GL, Reig A, Viñas O, Mahler M, Wunsch E, Milkiewicz P, Swain MG, Mason A, Stinton LM, Aparicio MB, Aldegunde MJ, Fritzler MJ, Parés A. The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center Study. Front Immunol 2019;10:662. [PMID: 31001269 DOI: 10.3389/fimmu.2019.00662] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
17 Karlsen TH, Vesterhus M, Boberg KM. Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis. Aliment Pharmacol Ther 2014;39:282-301. [DOI: 10.1111/apt.12581] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 6.2] [Reference Citation Analysis]
18 Granito A, Muratori P, Quarneti C, Pappas G, Cicola R, Muratori L. Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Rev Mol Diagn 2012;12:65-74. [PMID: 22133120 DOI: 10.1586/erm.11.82] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
19 Invernizzi P. Liver auto-immunology: the paradox of autoimmunity in a tolerogenic organ. J Autoimmun. 2013;46:1-6. [PMID: 24012346 DOI: 10.1016/j.jaut.2013.08.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
20 Tanaka T, Zhang W, Sun Y, Shuai Z, Chida AS, Kenny TP, Yang GX, Sanz I, Ansari A, Bowlus CL, Ippolito GC, Coppel RL, Okazaki K, He XS, Leung PSC, Gershwin ME. Autoreactive monoclonal antibodies from patients with primary biliary cholangitis recognize environmental xenobiotics. Hepatology 2017;66:885-95. [PMID: 28470667 DOI: 10.1002/hep.29245] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
21 Tanaka A. Current understanding of primary biliary cholangitis. Clin Mol Hepatol 2021;27:1-21. [PMID: 33264835 DOI: 10.3350/cmh.2020.0028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145-172. [PMID: 28427765 DOI: 10.1016/j.jhep.2017.03.022] [Cited by in Crossref: 409] [Cited by in F6Publishing: 326] [Article Influence: 81.8] [Reference Citation Analysis]
23 Huang C, Han W, Wang C, Liu Y, Chen Y, Duan Z. Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis. Dis Markers 2019;2019:9121207. [PMID: 31737133 DOI: 10.1155/2019/9121207] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
24 Bogdanos DP, Smyk DS, Invernizzi P, Rigopoulou EI, Blank M, Pouria S, Shoenfeld Y. Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev. 2013;12:726-740. [PMID: 23266520 DOI: 10.1016/j.autrev.2012.12.005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 6.5] [Reference Citation Analysis]
25 Rong G, Zhong R, Lleo A, Leung PS, Bowlus CL, Yang GX, Yang CY, Coppel RL, Ansari AA, Cuebas DA. Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. Hepatology. 2011;54:196-203. [PMID: 21488079 DOI: 10.1002/hep.24355] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
26 Chascsa DM, Lindor KD. Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: Is It Really the Same Disease? Clin Liver Dis. 2018;22:589-601. [PMID: 30259855 DOI: 10.1016/j.cld.2018.03.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Smyk D, Cholongitas E, Kriese S, Rigopoulou EI, Bogdanos DP. Primary biliary cirrhosis: family stories. Autoimmune Dis. 2011;2011:189585. [PMID: 21687641 DOI: 10.4061/2011/189585] [Cited by in Crossref: 13] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
28 Floreani A, Tanaka A, Bowlus C, Gershwin ME. Geoepidemiology and changing mortality in primary biliary cholangitis. J Gastroenterol 2017;52:655-62. [DOI: 10.1007/s00535-017-1333-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
29 Invernizzi P, Alessio MG, Smyk DS, Lleo A, Sonzogni A, Fabris L, Candusso M, Bogdanos DP, Iorio R, Torre G. Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. BMC Gastroenterol 2012;12:92. [PMID: 22816667 DOI: 10.1186/1471-230X-12-92] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
30 Bizzaro N, Covini G, Rosina F, Muratori P, Tonutti E, Villalta D, Pesente F, Alessio MG, Tampoia M, Antico A, Platzgummer S, Porcelli B, Terzuoli L, Liguori M, Bassetti D, Brusca I, Almasio PL, Tarantino G, Bonaguri C, Agostinis P, Bredi E, Tozzoli R, Invernizzi P, Selmi C. Overcoming a “Probable” Diagnosis in Antimitochondrial Antibody Negative Primary Biliary Cirrhosis: Study of 100 Sera and Review of the Literature. Clinic Rev Allerg Immunol 2012;42:288-97. [DOI: 10.1007/s12016-010-8234-y] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
31 Koutsoumpas AL, Kriese S, Rigopoulou EI. Popular and unpopular infectious agents linked to primary biliary cirrhosis. Auto Immun Highlights 2012;3:95-104. [PMID: 26000132 DOI: 10.1007/s13317-012-0039-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Milkiewicz M, Caballería L, Smyk DS, Milkiewicz P. Predicting and preventing autoimmunity: the case of anti-mitochondrial antibodies. Auto Immun Highlights 2012;3:105-12. [PMID: 26000133 DOI: 10.1007/s13317-012-0038-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
33 Smyk DS, Mytilinaiou MG, Grammatikopoulos T, Knisely AS, Mieli-Vergani G, Bogdanos DP, Vergani D. Primary biliary cirrhosis-specific antimitochondrial antibodies in neonatal haemochromatosis. Clin Dev Immunol 2013;2013:642643. [PMID: 24171034 DOI: 10.1155/2013/642643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
34 Bauer A, Habior A. Detection of Autoantibodies Against Nucleoporin p62 in Sera of Patients With Primary Biliary Cholangitis. Ann Lab Med 2019;39:291-8. [PMID: 30623621 DOI: 10.3343/alm.2019.39.3.291] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
35 Smyk DS, Orfanidou T, Invernizzi P, Bogdanos DP, Lenzi M. Vitamin D in autoimmune liver disease. Clin Res Hepatol Gastroenterol. 2013;37:535-545. [PMID: 23845396 DOI: 10.1016/j.clinre.2013.05.016] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
36 Dalekos GN, Gatselis NK. Variant and Specific Forms of Autoimmune Cholestatic Liver Diseases. Arch Immunol Ther Exp (Warsz) 2019;67:197-211. [PMID: 31165900 DOI: 10.1007/s00005-019-00550-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
37 Peng X, Tang J, Wu Y, Yang B, Hu J. Novel method for ANA quantitation using IIF imaging system. J Immunol Methods 2014;404:52-8. [PMID: 24370749 DOI: 10.1016/j.jim.2013.12.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
38 Smyk DS, Mytilinaiou MG, Milkiewicz P, Rigopoulou EI, Invernizzi P, Bogdanos DP. Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22. Auto Immun Highlights 2012;3:1-9. [PMID: 26000122 DOI: 10.1007/s13317-011-0023-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
39 Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S, Patanwala I, Pereira SP, Thain C, Thorburn D, Tiniakos D, Walmsley M, Webster G, Jones DEJ. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018;67:1568-94. [PMID: 29593060 DOI: 10.1136/gutjnl-2017-315259] [Cited by in Crossref: 93] [Cited by in F6Publishing: 69] [Article Influence: 23.3] [Reference Citation Analysis]
40 Bonaguri C, Melegari A, Picanza A, Russo A, De Santis E, Trenti T, Parmeggiani M, Belloni L, Savi E, de'Angelis GL, Gaiani F, Ferrari C, Lippi G. Association of solid-phase assays to the indirect immunofluorescence in primary biliary cholangitis diagnosis: Results of an Italian multicenter study. Autoimmunity Reviews 2019;18:102389. [DOI: 10.1016/j.autrev.2019.102389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Chen RC, Naiyanetr P, Shu SA, Wang J, Yang GX, Kenny TP, Guggenheim KC, Butler JD, Bowlus C, Tao MH. Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. Hepatology. 2013;57:1498-1508. [PMID: 23184636 DOI: 10.1002/hep.26157] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
42 Gatselis NK, Dalekos GN. Molecular diagnostic testing for primary biliary cholangitis. Expert Review of Molecular Diagnostics 2016;16:1001-10. [DOI: 10.1080/14737159.2016.1217159] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
43 Kivity S, Gilburd B, Agmon-levin N, Carrasco MG, Tzafrir Y, Sofer Y, Mandel M, Buttner T, Roggenbuck D, Matucci-cerinic M, Danko K, Hoyos ML, Shoenfeld Y. A novel automated indirect immunofluorescence autoantibody evaluation. Clin Rheumatol 2012;31:503-9. [DOI: 10.1007/s10067-011-1884-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
44 Shimoda S, Tsuneyama K, Kikuchi K, Harada K, Nakanuma Y, Nakamura M, Ishibashi H, Hisamoto S, Niiro H, Leung PS. The role of natural killer (NK) and NK T cells in the loss of tolerance in murine primary biliary cirrhosis. Clin Exp Immunol. 2012;168:279-284. [PMID: 22519590 DOI: 10.1111/j.1365-2249.2012.04581.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
45 Bogdanos DP, Smyk DS, Invernizzi P, Rigopoulou EI, Blank M, Sakkas L, Pouria S, Shoenfeld Y. Tracing environmental markers of autoimmunity: introducing the infectome. Immunol Res 2013;56:220-40. [PMID: 23592050 DOI: 10.1007/s12026-013-8399-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
46 Leung PS, Wang J, Naiyanetr P, Kenny TP, Lam KS, Kurth MJ, Gershwin ME. Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA. J Autoimmun. 2013;41:79-86. [PMID: 23352659 DOI: 10.1016/j.jaut.2012.12.007] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
47 Achenza MI, Meda F, Brunetta E, Selmi C. Serum autoantibodies for the diagnosis and management of autoimmune liver diseases. Expert Rev Gastroenterol Hepatol. 2012;6:717-729. [PMID: 23237257 DOI: 10.1586/egh.12.58] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
48 Bauer A, Habior A, Kraszewska E. Detection of anti-SP100 antibodies in primary biliary cirrhosis. Comparison of ELISA and immunofluorescence. J Immunoassay Immunochem. 2013;34:346-355. [PMID: 23859785 DOI: 10.1080/15321819.2012.741088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
49 Selmi C, Gershwin ME. Chronic Autoimmune Epithelitis in Sjögren's Syndrome and Primary Biliary Cholangitis: A Comprehensive Review. Rheumatol Ther 2017;4:263-79. [PMID: 28791611 DOI: 10.1007/s40744-017-0074-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
50 Cancado EL, Harriz M. The Importance of Autoantibody Detection in Primary Biliary Cirrhosis. Front Immunol. 2015;6:309. [PMID: 26157439 DOI: 10.3389/fimmu.2015.00309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
51 Podda M, Selmi C, Lleo A, Moroni L, Invernizzi P. The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. Journal of Autoimmunity 2013;46:81-7. [DOI: 10.1016/j.jaut.2013.06.015] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
52 Kawata K, Kobayashi Y, Gershwin ME, Bowlus CL. The Immunophysiology and Apoptosis of Biliary Epithelial Cells: Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clin Rev Allergy Immunol. 2012; Jun 12. [Epub ahead of print]. [PMID: 22689287 DOI: 10.1007/s12016-012-8324-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
53 Sahebjam F, Vierling JM. Autoimmune hepatitis. Front Med 2015;9:187-219. [DOI: 10.1007/s11684-015-0386-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
54 Moritoki Y, Tsuda M, Tsuneyama K, Zhang W, Yoshida K, Lian ZX, Yang GX, Ridgway WM, Wicker LS, Ansari AA. B cells promote hepatic inflammation, biliary cyst formation, and salivary gland inflammation in the NOD.c3c4 model of autoimmune cholangitis. Cell Immunol. 2011;268:16-23. [PMID: 21349500 DOI: 10.1016/j.cellimm.2011.01.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
55 Selmi C. Autoimmunity in 2010. Autoimmun Rev. 2011;10:725-732. [PMID: 21763468 DOI: 10.1016/j.autrev.2011.06.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
56 Ben Lamine Z, Ben Jazia I, Ben Ahmed M, Ben Slama A, Baccouche A, Slama F, Jemaa A, Ghedira I, Mankaï A. Anti-gp210 and anti-Sp100 antibodies in primary biliary cholangitis. Arab J Gastroenterol 2021:S1687-1979(21)00028-9. [PMID: 34090832 DOI: 10.1016/j.ajg.2021.05.006] [Reference Citation Analysis]
57 Alfano AM, Romito A, Marchese C, Battistini M, Crotti G, Ferrini A, Mancinetti C, Manetta T, Mengozzi G, Merlach P, Migliardi M, Tambuzzo MT. Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: Is it possible to predict the course of the disease? Immunol Res 2017;65:299-306. [PMID: 27475095 DOI: 10.1007/s12026-016-8838-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
58 Czaja AJ. Performance parameters of the conventional serological markers for autoimmune hepatitis. Dig Dis Sci. 2011;56:545-554. [PMID: 21127976 DOI: 10.1007/s10620-010-1501-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
59 Smyk DS, Rigopoulou EI, Pares A, Billinis C, Burroughs AK, Muratori L, Invernizzi P, Bogdanos DP. Sex differences associated with primary biliary cirrhosis. Clin Dev Immunol. 2012;2012:610504. [PMID: 22693524 DOI: 10.1155/2012/610504] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
60 Bianchi I, Lleo A, Bernuzzi F, Caliari L, Smyk DS, Invernizzi P. The X-factor in primary biliary cirrhosis: monosomy X and xenobiotics. Auto Immun Highlights 2012;3:127-32. [PMID: 26000136 DOI: 10.1007/s13317-012-0043-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Smyk DS, Rigopoulou EI, Muratori L, Burroughs AK, Bogdanos DP. Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. Annals of Hepatology 2012;11:7-14. [DOI: 10.1016/s1665-2681(19)31481-4] [Cited by in Crossref: 25] [Article Influence: 2.5] [Reference Citation Analysis]
62 Cinquanta L, Infantino M, Bizzaro N. Detecting Autoantibodies by Multiparametric Assays: Impact on Prevention, Diagnosis, Monitoring, and Personalized Therapy in Autoimmune Diseases. J Appl Lab Med 2022;7:137-50. [PMID: 34996071 DOI: 10.1093/jalm/jfab132] [Reference Citation Analysis]
63 Carbone M, Ronca V, Bruno S, Invernizzi P, Mells GF. Toward precision medicine in primary biliary cholangitis. Digestive and Liver Disease 2016;48:843-50. [DOI: 10.1016/j.dld.2016.05.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
64 Saverino D, Pesce G, Antola P, Porcelli B, Brusca I, Villalta D, Tampoia M, Tozzoli R, Tonutti E, Alessio MG, Bagnasco M, Bizzaro N. High levels of soluble CTLA-4 are present in anti-mitochondrial antibody positive, but not in antibody negative patients with primary biliary cirrhosis. PLoS One 2014;9:e112509. [PMID: 25383768 DOI: 10.1371/journal.pone.0112509] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
65 Terziroli Beretta-piccoli B, Mieli-vergani G, Vergani D. The clinical usage and definition of autoantibodies in immune-mediated liver disease: A comprehensive overview. Journal of Autoimmunity 2018;95:144-58. [DOI: 10.1016/j.jaut.2018.10.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
66 Ronca V, Gerussi A, Cristoferi L, Carbone M, Invernizzi P. Precision medicine in primary biliary cholangitis. J Dig Dis 2019;20:338-45. [PMID: 31099953 DOI: 10.1111/1751-2980.12787] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
67 Vierling JM. Diagnosis and treatment of autoimmune hepatitis. Curr Gastroenterol Rep. 2012;14:25-36. [PMID: 22179843 DOI: 10.1007/s11894-011-0236-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
68 Rigopoulou EI, Smyk DS, Matthews CE, Billinis C, Burroughs AK, Lenzi M, Bogdanos DP. Epstein-barr virus as a trigger of autoimmune liver diseases. Adv Virol. 2012;2012:987471. [PMID: 22693505 DOI: 10.1155/2012/987471] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
69 Yang CY, Leung PS, Yang GX, Kenny TP, Zhang W, Coppel R, Norman GL, Ansari AA, Mackay IR, Worman HJ. Epitope-specific anti-nuclear antibodies are expressed in a mouse model of primary biliary cirrhosis and are cytokine-dependent. Clin Exp Immunol. 2012;168:261-267. [PMID: 22519587 DOI: 10.1111/j.1365-2249.2012.04577.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
70 Wang JJ, Yang GX, Zhang WC, Lu L, Tsuneyama K, Kronenberg M, Véla JL, Lopez-Hoyos M, He XS, Ridgway WM. Escherichia coli infection induces autoimmune cholangitis and anti-mitochondrial antibodies in non-obese diabetic (NOD).B6 (Idd10/Idd18) mice. Clin Exp Immunol. 2014;175:192-201. [PMID: 24128311 DOI: 10.1111/cei.12224] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
71 Marzorati S, Invernizzi P, Lleo A. Making Sense of Autoantibodies in Cholestatic Liver Diseases. Clinics in Liver Disease 2016;20:33-46. [DOI: 10.1016/j.cld.2015.08.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
72 Bizzaro N, Tozzoli R, Villalta D. Autoimmune diagnostics: the technology, the strategy and the clinical governance. Immunol Res 2015;61:126-34. [DOI: 10.1007/s12026-014-8587-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
73 Hu S, Zhao F, Wang Q, Chen WX. The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis. Clin Chem Lab Med. 2014;52:1533-1542. [PMID: 24501161 DOI: 10.1515/cclm-2013-0926] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
74 Juliusson G, Imam M, Björnsson ES, Talwalkar JA, Lindor KD. Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. Scand J Gastroenterol. 2016;51:745-752. [PMID: 26776319 DOI: 10.3109/00365521.2015.1132337] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
75 Liberal R, Grant CR, Sakkas L, Bizzaro N, Bogdanos DP. Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis. Clin Res Hepatol Gastroenterol. 2013;37:572-585. [PMID: 23876351 DOI: 10.1016/j.clinre.2013.04.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
76 Zheng B, Mora RA, Fritzler MJ, Satoh M, Bloch DB, Garcia-De La Torre I, Boylan K, Kohl K, Wener MH, Andrade LEC, Chan EKL. Establishment of international autoantibody reference standards for the detection of autoantibodies directed against PML bodies, GW bodies, and NuMA protein. Clin Chem Lab Med 2020;59:197-207. [PMID: 32776893 DOI: 10.1515/cclm-2020-0981] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Duarte-Rey C, Bogdanos D, Yang CY, Roberts K, Leung PS, Anaya JM, Worman HJ, Gershwin ME. Primary biliary cirrhosis and the nuclear pore complex. Autoimmun Rev. 2012;11:898-902. [PMID: 22487189 DOI: 10.1016/j.autrev.2012.03.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
78 Savarino E, Furnari M, de Bortoli N, Martinucci I, Bodini G, Ghio M, Savarino V. Gastrointestinal involvement in systemic sclerosis. Presse Med 2014;43:e279-91. [PMID: 25179275 DOI: 10.1016/j.lpm.2014.03.029] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
79 Smyk D, Rigopoulou EI, Zen Y, Abeles RD, Billinis C, Pares A, Bogdanos DP. Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis? World J Gastroenterol 2012; 18(35): 4855-4865 [PMID: 23002357 DOI: 10.3748/wjg.v18.i35.4855] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
80 Papamichalis PA, Zachou K, Papamichali RA, Ioannou M, Gatselis NK, Dalekos GN, Koukoulis GK. Promyelocytic Leukemia Antigen Expression: a Histological Marker for Primary Biliary Cholangitis Diagnosis? J Transl Int Med 2021;9:43-51. [PMID: 33850801 DOI: 10.2478/jtim-2021-0008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Hirschfield GM. Diagnosis of primary biliary cirrhosis. Best Pract Res Clin Gastroenterol. 2011;25:701-712. [PMID: 22117636 DOI: 10.1016/j.bpg.2011.10.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
82 Infantino M, Meacci F, Grossi V, Manfredi M, Benucci M, Merone M, Soda P. The burden of the variability introduced by the HEp-2 assay kit and the CAD system in ANA indirect immunofluorescence test. Immunol Res 2017;65:345-54. [PMID: 27456204 DOI: 10.1007/s12026-016-8845-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
83 You H, Ma X, Efe C, Wang G, Jeong SH, Abe K, Duan W, Chen S, Kong Y, Zhang D, Wei L, Wang FS, Lin HC, Yang JM, Tanwandee T, Gani RA, Payawal DA, Sharma BC, Hou J, Yokosuka O, Dokmeci AK, Crawford D, Kao JH, Piratvisuth T, Suh DJ, Lesmana LA, Sollano J, Lau G, Sarin SK, Omata M, Tanaka A, Jia J. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int 2022. [PMID: 35119627 DOI: 10.1007/s12072-021-10276-6] [Reference Citation Analysis]
84 Rigamonti C, Bogdanos DP, Mytilinaiou MG, Smyk DS, Rigopoulou EI, Burroughs AK. Primary biliary cirrhosis associated with systemic sclerosis: diagnostic and clinical challenges. Int J Rheumatol 2011;2011:976427. [PMID: 22187566 DOI: 10.1155/2011/976427] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
85 Bauer A, Habior A, Gawel D. Diagnostic and Clinical Value of Specific Autoantibodies against Kelch-like 12 Peptide and Nuclear Envelope Proteins in Patients with Primary Biliary Cholangitis. Biomedicines 2022;10:801. [DOI: 10.3390/biomedicines10040801] [Reference Citation Analysis]
86 Terziroli Beretta-Piccoli B, Stirnimann G, Mertens J, Semela D, Zen Y, Mazzucchelli L, Voreck A, Kolbus N, Merlo E, Di Bartolomeo C, Messina P, Cerny A, Costantini S, Vergani D, Mieli-Vergani G; Swiss PBC Cohort Study Group. Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines. J Autoimmun 2021;116:102578. [PMID: 33229138 DOI: 10.1016/j.jaut.2020.102578] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Bogdanos DP, Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta. 2011;412:502-512. [PMID: 21185272 DOI: 10.1016/j.cca.2010.12.019] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 5.6] [Reference Citation Analysis]
88 Leung PS, Lam K, Kurth MJ, Coppel RL, Gershwin ME. Xenobiotics and autoimmunity: does acetaminophen cause primary biliary cirrhosis? Trends Mol Med. 2012;18:577-582. [PMID: 22920894 DOI: 10.1016/j.molmed.2012.07.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
89 Villalta D, Sorrentino MC, Girolami E, Tampoia M, Alessio MG, Brusca I, Daves M, Porcelli B, Barberio G, Bizzaro N. Autoantibody profiling of patients with primary biliary cirrhosis using a multiplexed line-blot assay. Clinica Chimica Acta 2015;438:135-8. [DOI: 10.1016/j.cca.2014.08.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
90 Smyk DS, Bogdanos DP, Kriese S, Billinis C, Burroughs AK, Rigopoulou EI. Urinary tract infection as a risk factor for autoimmune liver disease: From bench to bedside. Clinics and Research in Hepatology and Gastroenterology 2012;36:110-21. [DOI: 10.1016/j.clinre.2011.07.013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]